Lipoprotein(a) Foundation: Did You Know That 63 Million Americans Have a High Risk of Inherited Cardiovascular Disease and May Not Know It?

Lp(a) Foundation Issues Heart Month Infographic to
Raise Awareness that a Simple Blood Test Could be the First Step in
Preventing up to 120,000 Cardiovascular Events Every Year

SAN CARLOS, Calif.–(BUSINESS WIRE)–Lipoprotein(a) Foundation:



Lipoprotein(a), also known as Lp(a), is currently the strongest
monogenetic risk factor for coronary heart disease and aortic
2 Unfortunately, for some
people, the first sign of disease is a heart attack or stroke.

• It is estimated that 1 in 5 people globally have inherited high
Lp(a): 63million in the U.S.4

• If an adult has high Lp(a), there is at least a 50% chance of
their children inheriting it.

• Poor lifestyle habits do not contribute to high Lipoprotein(a).
Diet and exercise has little to no impact on lowering Lp(a).

• In the 2013 ACC/AHA Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults, elevated levels of Lp(a) are associated with an increased
risk for a premature cardiovascular event. In 2010, the European
Atherosclerosis Society recommended screening for elevated Lp(a)
as a priority for reducing cardiovascular risk.



Up to 120,000 Lp(a) Related Cardiovascular Events Go Undetected
Each Year
1; Simple Blood Test Could be
First Step in Preventing

• Lp(a) concentrations can be measured by a simple blood test, but
it is not included in most standard lipid panel tests that check
cholesterol levels. 1

• A study recently published in JACC shows that the current
cholesterol guidelines miss 8% of people who have a cardiovascular
event whose only risk factor is high Lp(a).1

• When you consider 1.5 million cardiovascular events each year in
the U.S. 5, that equals 120,000 potentially preventable
events with proactive screening for Lp(a)1.



What Can People Do if They Have a Family History of
Cardiovascular Disease?

• Use the Family
Tree Sheet
to map out your family history of
cardiovascular disease.

• Talk to your doctor about Lp(a) testing to get an accurate risk
assessment and lower controllable risk factors until there is a
therapy for high Lp(a).

• Support patient advocacy to find a therapy and advocate for more
research for high Lp(a) at



The following cardiovascular event survivors and cardiovascular
disease experts are available to discuss hereditary risks of
cardiovascular disease associated with Lp(a):

• Sandra Revill Tremulis, Calif-based survivor and founder of
Lipoprotein(a) Foundation

• Lp(a) Foundation Patient Advocates / Survivors in Cities around
the Nation

• Sotirios (Sam) Tsimikas, MD, Director, Vascular Medicine,
University of California San Diego; Deputy Editor of the Journal
of the American College of Cardiology and Associate Editor of JACC
Cardiovascular Interventions

• Amit Khera, MD, MSc, Director of the Preventive Cardiology
Section, UT Southwestern Medical Center, Dallas, TX

1 Mortensen M, MD, PHD, Afzal S, MD, PHD et al. Primary Prevention
with Statins. ACC/AHA Risk-Based Approach Versus Trial-Based
Approaches to Guide Statin Therapy. Guide Statin Therapy. JACC.
2 CARDIoGRAMplusC4D Consortium, Deloukas P et al. Large-scale
association analysis identifies new risk loci for coronary artery
disease. Nat Genet. 2013 Jan;45(1):25-33

3 Thanassoulis G. et al. Genetic Associations with Valvular
calcification and aortic stenosis. N Engl J Med. 2013 Feb
7;368(6):503-12. doi: 10.1056/NEJMoa1109034

4 Nordestgaard F., Chapman J, et al. Lipoprotein(a) as a
cardiovascular risk factor current status. European Heart J.

5 CDC reference:


Lipoprotein(a) Foundation:
Chris K. Joseph, 510-435-4031